SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is currently driven by heightened investor focus on the upcoming May 14th presentation of clinical trial data, which many community members believe will validate the potential of their lead drug candidate. The stock is seeing increased attention from institutional players and high short interest, fueling active discussions about a potential squeeze and the company's long-term prospects in the dermatology and oncology sectors.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure and community frustration as investors debate whether current levels represent a deep-value buying opportunity or a structural decline. While some traders are aggressively accumulating, others are expressing concern over stagnant volume and a lack of recovery compared to the broader crypto market.

Stellar is an open-source, decentralized network co-founded in 2014 by Jed McCaleb and Joyce Kim to facilitate the fast and low-cost transfer of value across different currencies and assets globally. Managed by the non-profit Stellar Development Foundation, the project serves as a global infrastructure that connects banks, payment systems, and individuals to expand financial access to underserved populations. Its main value proposition lies in providing a bridge between traditional money and digital networks through the use of Anchors, which are trusted entities that hold deposits and issue credits on the ledger.  The network operates using the Stellar Consensus Protocol and a Federated Byzantine Agreement, where nodes choose trusted sets of other nodes to agree on the state of the ledger. This system ensures high throughput and fast finality, where transactions are considered permanent and irreversible within seconds. Key features include a built-in distributed exchange for trading assets without intermediaries and the Soroban platform for developing smart contracts. Users can also utilize the network for tokenizing real-world assets or accessing decentralized finance services like peer-to-peer lending.  Stellar's native token, XLM, is essential for maintaining network integrity by acting as an intermediary to find efficient exchange paths and preventing spam through small transaction fees and minimum account balance requirements. Unlike many other digital assets, the network has no inflation because the community voted to disable the automatic creation of new tokens. While the project received early funding from the payments company Stripe, it is now sustained by a global community of validators and developers rather than traditional venture capital.

Stellar Lumens

Stellar Lumens is trending as investors react to its role in a major DTCC tokenization initiative and potential institutional adoption, fueling both long-term optimism and intense community debate regarding the coin's price volatility and real-world utility.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending due to heightened investor interest surrounding potential regulatory developments and upcoming exchange-linked product launches, even as community sentiment remains divided over ongoing token emissions. Discussion is further amplified by the traction of the native meme coin $MERY.X, with investors closely debating the correlation between the two assets and the security benefits of their decentralized structures.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is trending as traders debate the impact of potential geopolitical de-escalation in the Strait of Hormuz against persistent supply concerns. Community sentiment is deeply divided, with bears emphasizing supply chain recovery and potential peace deals, while bulls argue that structural inventory shortages and the leverage inherent in the inverse ETF make it a high-risk but high-reward play.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending as investors debate the future of the company following a new, unsolicited acquisition bid from an Israeli consortium that values the stock higher than the previously agreed Hapag-Lloyd merger. The community is actively discussing the potential for a bidding war, the impact of Israel's "golden share" on regulatory approval, and the stock's intrinsic value amidst surging container shipping rates.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

The PEPE community remains highly polarized, with intense debate occurring between those speculating on potential price catalysts and skeptics who dismiss the token as a fading meme. Discussions are currently dominated by noise surrounding broader crypto market sentiment and speculative talk about the impact of political figures and regulatory developments on future liquidity.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending as investors digest a series of positive clinical trial updates and analyst price target upgrades, fueling optimism around the potential for its lead asset, gedatolisib. The community is actively debating the company's transition to a commercial-stage biotech, with strong focus on institutional accumulation, upcoming PDUFA catalysts, and persistent speculation regarding a potential acquisition by larger pharmaceutical players.

Aventus Network

Aventus Network is seeing heightened community discussion following a significant decline in its price, which has fueled speculation and questions regarding potential technical issues on trading platforms. While some investors are concerned about the sharp move, others are focusing on the project's long-term utility in enterprise appchains and its Aventus Cloud infrastructure.

The Ondo Foundation was founded in 2022 as an independently governed and nonprofit Cayman Islands Foundation Company with no beneficial owners. The Ondo Foundation assisted in the launch of the Ondo DAO, which deployed and currently governs Flux Finance, the first lending protocol supporting tokenized securities as collateral.  ONDO token holders are entrusted with shaping the future of the Ondo DAO so that it continues to pursue its mission to democratize access to institutional-grade finance. The Ondo DAO gives ONDO holders specific rights pertaining to Flux Finance, which is currently governed by the Ondo DAO.

Ondo

Ondo is attracting heavy investor attention as the community focuses on its role as a leader in real-world asset tokenization, despite ongoing debates regarding governance structure and the impact of pending regulatory clarity. Investors remain optimistic about its long-term potential in the RWA sector, with active community discussions highlighting the anticipation for upcoming governance votes and the potential for a market-wide rally linked to broader economic signals.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

Key PointsKyverna Therapeutics is a clinical-stage biopharmaceutical firm advancing cell therapies for autoimmune diseases...

Kyverna Therapeutics Names Greg Martini CFO

(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of 'Moderate Buy' from the five research firms that are covering the company, Marketbeat Ratings...

Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday

Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...

AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX

AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,500,000 shares of the company's stock, valued at approximately...

Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA

Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g...

Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX

Peapod Lane Capital LLC decreased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 42.3% during the 4th quarter, according to its most recent disclosure with the SEC. The...

Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright

HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday...

Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up   - Should You Buy?

Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up - Should You Buy...

Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.read more...

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Kyverna Therapeutics Inc.

Dow, Nasdaq, S&P 500 Futures Edge Higher After Trump Extends Iran Ceasefire: POET, NVTS, KYTX, TSLA Stocks Garner Focus Today

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.69	--	--	N/A
Q2 '26	-$0.68	-$0.63	7.13%	BEAT
Q1 '26	-$0.75	-$0.66	12.20%	BEAT
Q4 '25	-$0.85	-$0.80	5.99%	BEAT
Q3 '25	-$0.97	-$0.85	12.47%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings